Status:

NOT_YET_RECRUITING

OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure

Lead Sponsor:

Albert Schweitzer Ziekenhuis, Netherlands

Collaborating Sponsors:

Meril Life Sciences Pvt. Ltd.

Angiocare BV, Netherlands

Conditions:

Coronary Arterial Disease (CAD)

Percutaneous Coronary Intervention (PCI)

Eligibility:

All Genders

18+ years

Brief Summary

Implantation of a metallic drug-eluting stent (DES) is currently the gold standard in percutaneous coronary intervention (PCI). However, a DES has several limitations on the long-term, such as chronic...

Eligibility Criteria

Inclusion

  • Stable coronary artery disease with one or more significant epicardial stenosis in native coronary arteries suitable for OCT or IVUS-guided PCI with BRS implantation.
  • Subject must be at least 18 years of age
  • Written consent to participate in the study

Exclusion

  • Culprit lesions in the setting of acute coronary syndrome.
  • Lesions with severe calcification.
  • Lesions in a coronary artery with severe tortuosity.
  • Left main coronary artery lesions.
  • Bifurcation lesions.
  • Ostial lesions.
  • Lesions with a difference in proximal and distal reference diameter of \>0.5 mm by visual judgement of the coronary angiogram by the treating operator.
  • Treatment of in-stent restenosis or stent thrombosis.
  • History of definite stent thrombosis.
  • Lesions in coronary artery bypass grafts.
  • Lesions not suitable for OCT or IVUS catheter delivery and imaging, e.g. due to tortuosity or distal localisation.
  • Creatinine Clearance ≤ 30 ml/min/1.73 m2 as calculated by MDRD formula for estimated GFR.
  • Contraindication to dual antiplatelet therapy with aspirin and a P2Y12 inhibitor or (if indicated) NOAC and P2Y12 inhibitor.
  • Planned non-deferrable major surgery after PCI.
  • Known comorbidity associated with a life expectancy \<1 year.
  • Unable to understand and follow study-related instructions or unable to comply with study protocol.

Key Trial Info

Start Date :

September 1 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2030

Estimated Enrollment :

117 Patients enrolled

Trial Details

Trial ID

NCT06919562

Start Date

September 1 2025

End Date

August 1 2030

Last Update

July 15 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.